Factor IX, Fc fusion protein (Recombinant)]: The company has various U.S. patents and patent applications, and a number of corresponding foreign counterparts, related to ELOCTATE and ALPROLIX, its long-lasting recombinant Factor VIII and Factor IX product candidates and their use, including U.S. patents nos. 7,404,956, 8,329,182, 7,348,004 and 7,862,820. These patents would expire between 2024 and 2025, and some may be entitled to additional patent term pursuant to the patent term adjustment or patent term extension provisions of the U.S. patent laws. Significant Events In March 2014, Biogen Idec announced another collaboration with Eisai Co. Ltd., to develop and commercialize potential treatments for Alzheimer's disease. In March 2014, Whitehead Institute announced it has entered into a scientific research collaboration with Biogen Idec aimed at driving early stage research that may lead to the development of novel therapies across a range of disease areas. In April 214, Biogen Idec has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties. In January 2014, Biogen Idec entered into an exclusive worldwide collaboration and license agreement with Sangamo BioSciences focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. In April 2014, Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement. The multi-year collaboration is designed to leverage the expertise and experience from both organizations to optimize Biogen Idec's clinical development processes. Regulation The company is subject to various federal and foreign laws that govern its international business practices with respect to payments to government officials. Those laws include the U.S. Foreign Corrupt Practices Act, which prohibits the U.S. companies and their representatives from paying, offering to pay, promising, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. The laws to which the company is subject also include the U.K. Bribery Act 2010, which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official, and failing to have adequate procedures to prevent employees and other agents from giving bribes. Significant Events In May 2014, Eisai Co., Ltd. has expanded collaboration with Biogen Idec to develop and commercialize its clinical candidates for Alzheimer's disease, or AD, in Japan. Competition AVONEX and TYSABRI: The company competes with Teva Pharmaceutical Industries Ltd.; Merck; the Bayer Group; Novartis AG; and Sanofi-Aventis Deutschland GmbH. RITUXAN IN ONCOLOGY: The company competes with Cephalon, Inc. and GenMab. RITUXAN IN RHEUMATOID ARTHRITIS: The company competes with Johnson & Johnson; AbbVie, Inc.; Amgen, Inc.; Pfizer Inc.; UCB, S.A.; Bristol-Myers Squibb Company; and Roche. History The company was founded as a California corporation in 1985 and became a Delaware corporation in 1997. It was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in 2003.
biogen idec inc (IDP:Frankfurt)
225 Binney Street
Cambridge, MA 02142
|AbbVie Inc||$61.85 USD||-1.25|
|Astellas Pharma Inc||¥1,823 JPY||+14.00|
|Celgene Corp||$118.97 USD||-3.39|
|Novo Nordisk A/S||kr300.00 DKK||+1.60|
|Shire PLC||4,890 GBp||+10.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BIOGEN IDEC INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.